Pilot Study to Assess Dimethyl Fumarate Related GI Symptom Mitigation (IIT9)
A Pilot Study to Assess Dimethyl Fumarate (Tecfidera) Related GI Symptom Mitigation Via Food Bolus Alteration and Simethicone/Loperamide Administration
Sponsor: Biogen
Terminated
Study did not meet required enrollment numbers
Other terminated trials from Biogen
Other Relapsing Remitting Multiple Sclerosis trials with similar outcome
A PHASE4 clinical study on Relapsing Remitting Multiple Sclerosis, this trial is terminated or withdrawn. The trial is conducted by Biogen and has accumulated 8 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE4
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE4
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE4
▶ Show 3 earlier versions
-
May 2017 — Jun 2018 [monthly]
Terminated PHASE4
-
Feb 2017 — May 2017 [monthly]
Terminated PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE4
First recorded
Jul 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Biogen
- Rocky Mountain MS Research Group, LLC
For direct contact, visit the study record on ClinicalTrials.gov .